Buy Generic Letrozole Online

Cheap version of Generic Femara, Letronat / Fempro – Prices

Active substance: Letrozole
U.S. Brand: Femara
Indian Brand: Fempro, Letronat
Made by: |
Strength: 2.5 mg
Form release: blister with 10 tablets
Shipping time: 7 – 21 days
Best price: 0.39 USD
through request form

DescriptionHow to take?Common Side EffectsLatest New'sPhoto's

Generic Femara (letrozole) is a non-steroidal aromatase inhibitor (lowers estrogen production) used to treat breast cancer in postmenopausal women. Femara is often given to women who have been taking tamoxifen (Nolvadex) for 5 years. Femara is available in generic form. Letrozole is also used in women who have experienced menopause as a first treatment of breast cancer that has spread within the breast or to other areas of the body or in women whose breast cancer has worsened while they were taking tamoxifen. Letrozole is in a class of medications called nonsteroidal aromatase inhibitors. It works by decreasing the amount of estrogen produced by the body. This can slow or stop the growth of some types of breast cancer cells that need estrogen to grow.

You have letrozole as a tablet once a day. It is best to take the tablets at the same time each day. You can take them with or without food. Take letrozole at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take letrozole exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Raised cholesterol levels 

You can have raised cholesterol levels in the blood. This is usually only slightly raised and you will have regular blood tests to check the levels.

Hot flushes

We have some tips for coping with hot flushes and the possible treatments for men and women. Talk to your doctor if your hot flushes are hard to cope with. They might be able to prescribe you some medicines.

Increased sweating

You might sweat more than usual especially under the arms and your hands and feet. Tell your doctor or nurse they may be able to help.

Joint and muscle pain

You might feel some pain from your muscles and joints. Speak to your doctor or nurse about what painkillers you can take to help with this.

Gut microbiome could hold key for PCOS treatment

The researchers found that the mice treated with letrozole gained more weight and had increased insulin resistance compared with mice given placebo, but that cohousing mitigated these developments. Testosterone and luteinizing hormone levels rose for letrozole-treated mice housed together, whereas the cohoused mice had normal testosterone and LH levels and experienced normal estrous cycling and ovulation.

Thackray and colleagues also observed a shift toward similar gut microbiomes in the cohoused mice, which she said indicated that “there is an exchange of microbes between these two groups.” Additional analysis revealed that the bacteria Coprobacillus changed when comparing letrozole-treated mice housed together and letrozole-treated mice in the cohousing group, indicating that this specific bacteria “potentially could be a probiotic that we can test as a potential treatment for protecting or preventing the development of PCOS,” Thackray said during a press conference.

“This cohousing approach suggests that the changes that we see in the microbiome are not just a result of PCOS, but it may actually play a causal role,” Thackray said. “Fundamentally, this is suggesting that modulation of the gut microbiome could be a potential therapy for PCOS. We’d like to follow this up with our mouse model, with the eventual goal of developing new therapeutics for women with PCOS.” – by Phil Neuffer

Upfront Combo Shows Improved OS in Metastatic Breast Cancer

Women with metastatic hormone-sensitive breast cancer lived nearly 8 months longer with the addition of fulvestrant (Faslodex) to first-line anastrozole (Arimidex), long-term results of a phase III trial showed.

In the study of nearly 700 patients, overall survival (OS) in the combination arm was 49.8 months versus 42.0 months with anastrozole alone at 7 years median follow-up (HR 0.82, 95% CI 0.69-0.98, P=0.03), Rita S. Mehta, MD, of the University of California, Irvine, and colleagues reported.

At 5 years, 42% of patients in the combination arm were still alive compared with 33% in the anastrozole arm, despite nearly half the women in the control arm crossing over to fulvestrant, a selective estrogen-receptor down-regulator, after disease progression, they wrote in the New England Journal of Medicine.

Mehta told MedPage Today that until now, first-line metastatic breast cancer trials have shown improvements in progression-free survival (PFS) but not OS.

“If we don’t see a survival benefit with newer agents compared to old agents, then we haven’t really moved the needle,” she said. “Ultimately patients want to see if they can live longer or not.”

Early findings from SWOG S0226 were first reported by Mehta in 2011, at a median 3 years follow-up, and showed a significant PFS benefit with the combination (15.0 vs 13.5 months) and a trend toward improved OS.

“Some physicians changed their practice back then — some were not convinced,” Mehta said. “But now they should be convinced, because now we have one of the longest follow-ups and one of the largest studies.”

The current study, SWOG Cancer Research Network S0226, examined outcomes of 694 women randomized 1:1 to standard-dose anastrozole or the combination of anastrozole plus intramuscular fulvestrant. Patients were stratified by prior use of tamoxifen. All patients had hormone receptor-positive disease.

Further subgroup analyses for OS in the updated findings showed no benefit for the combination among those whose disease progressed from 5 to 10 years from their initial breast cancer diagnosis (HR 1.01, 95% CI 0.69-1.48) and in patients not sensitive to endocrine therapy (HR 1.08, 95% CI 0.64-1.80).

Mehta noted that with the longer follow-up, there were no additional grade 4/5 adverse events (AEs) on the combination arm. “In fact, if there was any additional grade 4 toxicity it was on the anastrozole arm,” she said.

Previous grade 4 AEs in the combination arm included arthralgia, dyspnea, thrombosis or embolism, and thrombocytopenia, each occurring in one patient, and there were three treatment-related deaths in the combination arm — all previously reported.

Grade 3 toxicities were similar between the two arms, at 15% of patients on the combination and 13% of those on anastrozole-alone (P=0.47). The most common grade 3 AEs (ranging from 1% to 4%) were fatigue, GI symptoms, hot flashes, mood alterations, and musculoskeletal pain. Treatment discontinuation due to AEs were rare — 12 patients on the combination and five on anastrozole alone.

Breast Cancer Drug Shown to Impair Brain Function

A study in nonhuman primates by researchers at the University of Massachusetts and the University of Maryland School of Medicine has shown that the breast cancer drug letrozole has adverse effects on the brain. Letrozole is an aromatase inhibitor (AI) that is often given as adjuvant therapy to women with estrogen receptor-dependent breast cancer, but the treatment is linked with side effects including hot flashes and mood changes. The new studies, carried out in both male and female marmosets, showed that letrozole therapy caused behavior changes consistent with central nervous system (CNS) symptoms, and negatively impacted on the physiology of neurons in the brain’s hippocampus region.

Reporting their studies in the Journal of Neuroscience, Nicole Gervais, Ph.D., and colleagues say their findings highlight the need both for greater understanding of the mechanisms that underlie how AIs impact on brain function, and also “the development of new treatment approaches for breast cancer patients that minimize adverse effects on the brain.” Their paper is titled, “Adverse effects of aromatase inhibition on the brain and behavior in a non-human primate.”

Estrogens are produced through the conversion of testosterone by the enzyme aromatase, and patients with estrogen receptor-dependent breast cancer are commonly treated using adjuvant aromatase inhibitors, such as letrozole, to prevent this conversion. AI therapy is also used for men with prostate or breast cancers. Unfortunately, AI drugs can cause side effects including insomnia, depression, hot flashes, and memory problems that may be severe enough for patients to discontinue treatment, the authors wrote. “However, the mechanisms by which AIs give rise to these CNS symptoms remain unclear,” they pointed out, as studies in humans often lack proper controls and are hampered by confounding factors such as concurrent chemotherapy/radiotherapy treatment, stress, and disease stage. There have also not been any systematic analyses of sex-related differences in side effects.

The researchers’ reported study was designed to investigate whether continuous letrozole therapy in the marmoset as a nonhuman primate model would cause similar side effects to those observed in humans, but without the muddying effects of confounding factors. Marmosets and humans have similar brain structural and functional organization, the researchers pointed out, and prior studies indicated that the two species also share similarities in sleep and thermoregulation patterns, cognitive ability, and anxiety profiles.

Nine male and seven female marmosets were given letrozole in their puddings for four weeks, and the effects of treatment on cognition, anxiety, thermoregulation, brain estrogen content, and hippocampal pyramidal cell32 physiology were assessed. “This was the first study using a nonhuman primate to examine the effects of letrozole on brain and behavior,” the researchers wrote.

The results in a nonhuman primate corroborate many of the symptoms reported by women taking AIs and reveal detrimental effects of these treatments on the brain, in part through elevated hippocampal E2 levels,” the researchers concluded. “Future studies are needed to elucidate the precise mechanisms by which AIs compromise the CNS.”

Submit your review

Create your own review

Average rating:  
 0 reviews